BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17264123)

  • 21. A cytoplasmic negative regulator isoform of ATF7 impairs ATF7 and ATF2 phosphorylation and transcriptional activity.
    Diring J; Camuzeaux B; Donzeau M; Vigneron M; Rosa-Calatrava M; Kedinger C; Chatton B
    PLoS One; 2011; 6(8):e23351. PubMed ID: 21858082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RanBP2-Mediated SUMOylation Promotes Human DNA Polymerase Lambda Nuclear Localization and DNA Repair.
    Moreno-Oñate M; Herrero-Ruiz AM; García-Dominguez M; Cortés-Ledesma F; Ruiz JF
    J Mol Biol; 2020 Jun; 432(13):3965-3979. PubMed ID: 32224012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription.
    Ling Y; Sankpal UT; Robertson AK; McNally JG; Karpova T; Robertson KD
    Nucleic Acids Res; 2004; 32(2):598-610. PubMed ID: 14752048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performing in vitro sumoylation reactions using recombinant enzymes.
    Werner A; Moutty MC; Möller U; Melchior F
    Methods Mol Biol; 2009; 497():187-99. PubMed ID: 19107418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification.
    Lee MB; Lebedeva LA; Suzawa M; Wadekar SA; Desclozeaux M; Ingraham HA
    Mol Cell Biol; 2005 Mar; 25(5):1879-90. PubMed ID: 15713642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription.
    Spengler ML; Brattain MG
    J Biol Chem; 2006 Mar; 281(9):5567-74. PubMed ID: 16407261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
    Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
    Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of sumoylation.
    Pichler A
    Methods Mol Biol; 2008; 446():131-8. PubMed ID: 18373254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUMO modification regulates the transcriptional activity of MAML1.
    Lindberg MJ; Popko-Scibor AE; Hansson ML; Wallberg AE
    FASEB J; 2010 Jul; 24(7):2396-404. PubMed ID: 20203086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repression of Smad4 transcriptional activity by SUMO modification.
    Long J; Wang G; He D; Liu F
    Biochem J; 2004 Apr; 379(Pt 1):23-9. PubMed ID: 14750902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors.
    Grégoire S; Yang XJ
    Mol Cell Biol; 2005 Mar; 25(6):2273-87. PubMed ID: 15743823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opposing biological functions of the cytoplasm and nucleus DAXX modified by SUMO-2/3 in gastric cancer.
    Chen C; Sun X; Xie W; Chen S; Hu Y; Xing D; Xu J; Chen X; Zhao Z; Han Z; Xue X; Shen X; Lin K
    Cell Death Dis; 2020 Jul; 11(7):514. PubMed ID: 32641734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation.
    Depaux A; Regnier-Ricard F; Germani A; Varin-Blank N
    Oncogene; 2007 Oct; 26(46):6665-76. PubMed ID: 17533377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Getting hit by SUMO.
    Ferrier V
    Nat Cell Biol; 2002 Mar; 4(3):E57. PubMed ID: 11875448
    [No Abstract]   [Full Text] [Related]  

  • 35. Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity.
    Kang J; Gocke CB; Yu H
    BMC Biochem; 2006 Feb; 7():5. PubMed ID: 16478538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DNA binding of Sox2 by the SUMO conjugation.
    Tsuruzoe S; Ishihara K; Uchimura Y; Watanabe S; Sekita Y; Aoto T; Saitoh H; Yuasa Y; Niwa H; Kawasuji M; Baba H; Nakao M
    Biochem Biophys Res Commun; 2006 Dec; 351(4):920-6. PubMed ID: 17097055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.
    Schmidt D; Müller S
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2872-7. PubMed ID: 11867732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity.
    Berta MA; Mazure N; Hattab M; Pouysségur J; Brahimi-Horn MC
    Biochem Biophys Res Commun; 2007 Aug; 360(3):646-52. PubMed ID: 17610843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An extended consensus motif enhances the specificity of substrate modification by SUMO.
    Yang SH; Galanis A; Witty J; Sharrocks AD
    EMBO J; 2006 Nov; 25(21):5083-93. PubMed ID: 17036045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple domains in Siz SUMO ligases contribute to substrate selectivity.
    Reindle A; Belichenko I; Bylebyl GR; Chen XL; Gandhi N; Johnson ES
    J Cell Sci; 2006 Nov; 119(Pt 22):4749-57. PubMed ID: 17077124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.